Dr Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?

Dr Fabio Schutz graduated from Parana Federal University and did his internal medicine residency at Hospital de Clinicas in Curitiba - PR, Brazil. Then, he moved to São Paulo - SP for his medical oncology clinical fellowship at Hospital Sirio Libanes. After finishing his medical oncology fellowship, he worked for a couple of years as an assistant medical oncologist in the same hospital. From 2009 to 2011, he worked as a research fellow in genitourinary (GU) oncology in the Lank Center for GU Oncology at the Dana-Farber Cancer Institute - Harvard Medical School in Boston - MA, USA. He developed several original research projects and authored many manuscripts in high-impact journals. Since mid-2011, he is working as a medical oncologist of the BP - Beneficencia Portuguesa de Sao Paulo in Sao Paulo - SP, Brazil. He is most interested and is currently conducting clinical trials in GU cancers.

Dr Fabio Schutz has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, BMS, Janssen and Ipsen 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.
blueprint BluePrintInfographic / Flashcard
Oncology 
Biomarker testing in non-small cell lung cancer (NSCLC)

Insights from patients and caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr Rodrigo Paredes de la Fuente, Anne-Marie Baird, Amy C. Moore, Shani Shilo
Endorsed by
LUNGevity The Israeli Lung Cancer Foundation
Biomarker Collaborative NTRKers Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jul 2026

Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258
micro-learning Micro learning - Video, slides and more
Oncology 
The evolving treatment landscape in HER2-mutant NSCLC

Expert insights on how the latest evidence is shaping clinical practice

Experts
Dr Devika Das, Dr Tom Newsom-Davis
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer